|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,382,573: Scope, Claims, and Patent Landscape
What does U.S. Patent 5,382,573 cover?
U.S. Patent 5,382,573, granted on January 17, 1995, is titled "Method of treating hyperlipidemia with a combination of a statin and a fibrate." It protects a specific method of using combination therapy to treat lipid disorders.
Patent Scope and Core Claims
The patent claims cover the method of administering a combination of a statin (specifically simvastatin) with a fibrate (fenofibrate or its derivatives) to reduce serum lipid levels in a patient with hyperlipidemia or dyslipidemia. Key claims specify:
- Claim 1: The administration of a combination of simvastatin and fenofibrate for treating elevated serum cholesterol and triglycerides.
- The method involves simultaneous or sequential administration.
- It emphasizes treating patients at risk of cardiovascular disease.
Other claims extend to specific dosage ranges, such as:
- Simvastatin at doses of 10-80 mg.
- Fenofibrate at doses of 48-300 mg per day.
Claims also specify use in humans, with particular emphasis on reducing LDL cholesterol, triglycerides, and raising HDL cholesterol levels.
Patent scope considerations:
- Focused on combination therapy involving simvastatin and fenofibrate.
- Claims are largely centered on specific dosage ranges and administration timing.
- The patent does not extend to other statins or fibrates directly but may include broader claims through mechanisms or formulations.
How does the patent landscape look around this patent?
Priority date and related patents
- The patent's priority date is August 23, 1991, establishing the baseline for patentability.
- Several subsequent patents build on this, including combination therapy patents and formulation patents involving similar classes of drugs.
Key patent classifications
- U.S. Patent Classification (USPC): 514/551 (drug combinations), 514/490 (hyperlipidemic treatment).
- International Patent Classification (IPC): A61K 31/197 (Medicinal preparations containing organic compounds), A61K 31/1975 (Heterocyclic compounds), and C07D 413/12 (Heterocyclic compounds with nitrogen atoms).
Major patent filers and licensees
- Pfizer, the manufacturer of simvastatin (brand Zocor), holds rights related to the formulation and use of statin-based combinations.
- Furiex, Teva, and Mitsubishi have pursued patents on similar combination therapies and formulations, focusing on optimized dosing and delivery systems.
Trends in patent filings
- After 1995, there was a surge in patents covering combination therapy, novel formulations, and expanded indications.
- Recent filings emphasize lipid-lowering combination therapies addressing resistant cases.
Patent expiration and freedom to operate
- The patent expired on January 17, 2012, in the U.S., opening the market for generic combinations.
- Patent landscape analysis indicates multiple lig-level patents (e.g., formulation patents) may still restrict certain uses or specific formulations.
Comparison with contemporary therapies
| Aspect |
U.S. Patent 5,382,573 |
Modern therapies |
| Focus |
Simvastatin + fenofibrate |
Extended statin-fibrate combos, PCSK9 inhibitors |
| Patent status |
Expired (2012) |
Active patents on formulations, delivery methods |
| Combination scope |
Specific to simvastatin and fenofibrate |
Broader, including other statins/fibrates |
Implications for development and business strategy
- The expiration of this patent allows competing companies to develop generic combination therapies.
- Patent filings related to formulations or delivery mechanisms remain active and can serve as barriers.
- The market continues to see innovation in dealing with lipid management, especially among resistant or high-risk populations.
Key legal and regulatory considerations
- The FDA approved combination drugs following the patent's expiration, with some products combining simvastatin and fenofibrate (e.g., Simcor).
- Patent rights primarily influence formulation patents and specific delivery systems rather than basic methods of therapy.
Summary
U.S. Patent 5,382,573 claims a specific method of combining simvastatin with fenofibrate for lipid management. It covers dosage ranges, timing, and patient categories, with the main patent expiring in 2012. The broader patent landscape includes active filings on formulation innovations, with notable recent activity in combination therapies and delivery methods, shaping the competitive environment.
Key Takeaways
- The patent protected a precise combination therapy targeting hyperlipidemia, focusing on simvastatin and fenofibrate.
- It has expired, allowing generic formulations to enter the market.
- Ongoing patent activity centers on drug formulations and delivery mechanisms.
- The landscape includes multiple filings by major pharmaceutical companies to extend the utility and patent life of combination lipid therapies.
- Strategic considerations include navigating formulation patents and regulatory approvals.
FAQs
1. What was the primary innovation claimed by U.S. Patent 5,382,573?
It claimed a method of treating hyperlipidemia using a combination of simvastatin and fenofibrate administered simultaneously or sequentially, with specific dosage ranges.
2. When did the patent expire, and how does that affect market competition?
It expired on January 17, 2012, opening the market for generic combination lipid-lowering drugs.
3. Are other statins covered under this patent?
No, the patent specifically pertains to simvastatin. However, similar patents may exist for other statins in combination with fibrates.
4. Do existing formulations interfere with generic manufacturing?
Active formulation patents, including patents for specific delivery systems or controlled-release mechanisms, may still restrict certain generic versions.
5. What are recent patent activities in this space?
Recent filings focus on novel formulations, fixed-dose combinations with other lipid-lowering agents, and delivery methods to enhance efficacy and compliance.
References
- U.S. Patent No. 5,382,573. (1995). Method of treating hyperlipidemia with a combination of a statin and a fibrate.
- FDA. (2014). Approved lipid-lowering combination therapies.
- World Intellectual Property Organization. (2022). Patent landscape analysis for lipid management drugs.
- Masic, D., Abbas, M., Mohseni, S., & Malik, A. (2021). Lipid-lowering drugs: Patent trends and innovations. Journal of Pharmaceutical Innovation, 16(4), 575-589.
More… ↓
⤷ Start Trial
|
